SecBot SecBot

FRNM drug pipeline

Freenome, Inc. · 2 rated drugs
$10.09
−3.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.4%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready on the market. The FDA approved SimpleScreen CRC on July 27, 2026. Abbott commercially launched the test in the United States in late September 2026.

SimpleScreen CRC Updated Nov 14

What to watch

SimpleScreen CRC's defining binary (FDA approval) has passed, removing the high-impact binary catalyst. The stock now trades on the commercial execution story via Abbott and on pipeline expansion (lung test). Watch Q4 2026 revenue (due early 2027) for evidence of recurring test-sale volume versus one-time milestones; the next-gen validation data and a potential FDA filing for the updated version are the next potential catalysts to watch for.

Bull case
  • FDA-approved and commercially launched: the test is the second blood-based CRC screening test to reach the US market, and Abbott handles all US commercialization, giving Freenome a powerful distribution partner.
  • Q32026 results show the business model working: revenue jumped to $183.5 million (from $1 million) and EPS of $0.57 beat the $0.41 consensus, driven by milestone revenue from Abbott.
  • Analyst consensus is overwhelmingly bullish: 6 Strong Buy, 4 Buy, and only 1 Hold, with a mean price target of $18 (72.9% implied upside from $10.41).
Bear case
  • Competition is intensifying: Guardant Health's Shield blood test (approved 2024) has first-mover advantage and expanding insurance coverage. Abbott's ownership of both Cologuard Plus (stool) and SimpleScreen CRC (blood) may cannibalize one or the other.
  • Clinical performance is mid-tier: SimpleScreen CRC's ~81% sensitivity for colorectal cancer lags behind stool-based tests like Cologuard (over 90%) and colonoscopy (the gold standard). The test is positioned as a second-line option for those unwilling to do stool tests or colonoscopy, not as a replacement.
  • Stock dropped 11% in October 2026 after the next-gen data at ACG showed 'clinically meaningful' improvement but apparently disappointed expectations for bigger gains.
● neutral
Impact
PhaseCommercialized (LDT launch)
Time to marketAlready commercially available as a laboratory-developed test (LDT) as of October 20, 2026. A future FDA premarket approval submission is planned but no timeline has been announced.

SimpleScreen Lung Updated Nov 14

What to watch

SimpleScreen Lung was launched as an LDT on October 20, 2026, so the key binary event has passed. Watch for the company's progress toward FDA premarket submission (expedited by Breakthrough Device Designation), commercial adoption metrics, and payer coverage decisions, which will drive the stock over the coming quarters.

Bull case
  • SimpleScreen Lung showed 85% sensitivity and 99.8% negative predictive value in an independent cohort, a strong performance for a blood-based lung cancer screening test in a high-risk population (ages 50-80, >=20 pack-year smoking history).
  • The test is commercially launched and can be ordered alongside the FDA-approved SimpleScreen CRC test from a single blood draw, offering a differentiated 'personalized cancer detection' bundle.
  • Freenome has FDA Breakthrough Device Designation for SimpleScreen Lung, which provides prioritized review and enhanced FDA interaction for a future premarket approval submission.
Bear case
  • SimpleScreen Lung is launched as an LDT, not a fully FDA-approved test, which could limit physician adoption and payer reimbursement compared to FDA-authorized alternatives.
  • Lung cancer screening competition is intense: GRAIL's multi-cancer Galleri test received an FDA advisory panel endorsement in September 2026, while Guardant Health and Exact Sciences are expanding into multi-cancer blood testing.
  • At 50% specificity, SimpleScreen Lung may produce false positives in half of screened patients, potentially limiting clinical adoption versus tests with higher specificity.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Jul 27, 2026SimpleScreen CRCApproval−4.2%−2.0%
Jul 24, 2026SimpleScreen CRCApproval−6.7%−8.6%